pioglitazone and Bronchial Hyperreactivity studies

Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.
pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.

Bronchial Hyperreactivity: Tendency of the smooth muscle of the tracheobronchial tree to contract more intensely in response to a given stimulus than it does in the response seen in normal individuals. This condition is present in virtually all symptomatic patients with asthma. The most prominent manifestation of this smooth muscle contraction is a decrease in airway caliber that can be readily measured in the pulmonary function laboratory.

Research Excerpts

Excerpt	Relevance	Reference
"This pilot study suggests limited efficacy for pioglitazone in the treatment of poorly controlled asthma in obesity, and also the potential for harm, given the weight gain in those assigned to active treatment, and the association between increased weight and worse outcomes in asthma."	9.20	A pilot randomized controlled trial of pioglitazone for the treatment of poorly controlled asthma in obesity. ( Black, K; DeSarno, M; Dixon, AE; Holguin, F; Lane, L; Subramanian, M, 2015)
"Both insulin resistance and hyperinsulinemia are common in obesity."	5.62	Pioglitazone prevents obesity-related airway hyperreactivity and neuronal M ( Fryer, AD; Jacoby, DB; Nie, Z; Proskocil, BJ, 2021)
"This pilot study suggests limited efficacy for pioglitazone in the treatment of poorly controlled asthma in obesity, and also the potential for harm, given the weight gain in those assigned to active treatment, and the association between increased weight and worse outcomes in asthma."	5.20	A pilot randomized controlled trial of pioglitazone for the treatment of poorly controlled asthma in obesity. ( Black, K; DeSarno, M; Dixon, AE; Holguin, F; Lane, L; Subramanian, M, 2015)
"Both insulin resistance and hyperinsulinemia are common in obesity."	1.62	Pioglitazone prevents obesity-related airway hyperreactivity and neuronal M ( Fryer, AD; Jacoby, DB; Nie, Z; Proskocil, BJ, 2021)

Research

Studies (2)

Authors

Clinical Trials (1)

Trial Overview

Trial Outcomes

Airway Reactivity

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (50.00)	24.3611
2020's	1 (50.00)	2.80

Authors	Studies
Proskocil, BJ	1
Fryer, AD	1
Jacoby, DB	1
Nie, Z	1
Dixon, AE	1
Subramanian, M	1
DeSarno, M	1
Black, K	1
Lane, L	1
Holguin, F	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
A Randomized, Placebo-Controlled Pilot Study of Pioglitazone for the Treatment of Moderate to Severe Asthma in Obese Asthmatics[NCT00634036]	Phase 2	23 participants (Actual)	Interventional	2009-10-31	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Presence and degree of airway hyperresponsiveness assessed by methacholine challenge test. PC20= Methacholine dose at wich the FEV1 deops by > 20% from pre-methacholine baseline values. (NCT00634036)
Timeframe: 12 weeks

Exhaled Nitric Oxide Ppb

FEV1 % Predicted

Juniper Asthma Control Questionnaire

Intervention	mg/ml (Median)
Pioglitazone	5.08
Placebo	2.37

Intervention	ppb (Mean)
Pioglitazone	27.6
Placebo	30.8

Intervention	% predicted (Mean)
Pioglitazone	80.3
Placebo	85.2

The Juniper Asthma Control Questionnaire is a validated scale ranging from 0 to 6. Higher scores represent poorer asthma control. Values > 1.5 are compatible with poorly controlled asthma (NCT00634036)
Timeframe: 12 weeks

pioglitazone and Bronchial Hyperreactivity